Objective To explore the clinical efficacy of Calcipotriol combined with Acitretin Capsules in the treatment of common psoriasis vulgaris.Methods A total of 80 patients with common psoriasis vulgaris who were admitted to Guangdong Qingyuan Prevention and Treatment Hospital of Chronic Disease from January 2019 to October 2020 were selected.They were divided into two groups by random number table method,with 40 cases in each group.The control group was treated with Acitretin Capsules,and the study group was given Acitretin Capsules combined with Calcipotriol for treatment.All groups were treated for 30 days.The inflammatory factors(tumor necrosis factor-α [TNF-α],interleukin[IL]-23,IL-17),vascular endothelial growth factor(VEGF)levels,psoriasis lesion area and severity index(PASI)scores of patients in both groups before and after treatment were observed and compared,and the treatment effect were compared between the two groups.Results After treatment,TNF-α in study group was (94.23±1.08)μg/L,IL-23 in study group was(184.31±9.16)μg/L,IL-17 in study group was(92.16±6.63)μg/L,which were lower than those in the control group of(105.17±8.32),(207.41±10.69),(103.41±7.69)μg/L,the differences were statistically significant(P<0.05).After treatment,VEGF level in study group was(93.55±9.14)ng/ml,and PASI score in study group was(5.14±1.05)points,which were lower than those in control group of(114.30±10.80)ng/ml and(7.30±1.26)points,the differences were statistically significant(P<0.05).The total effective rate in study group(97.5%)was higher than that in control group(70.0%),and the difference was statistically significant(P<0.05).Conclusion Compared with Acitretin Capsules alone in the treatment of common psoriasis vulgaris,the combined application of Calcipotriol combined with Acitretin Capsules is more effective.It can improve the body′s inflammatory factor levels,reduce the PASI scores and VEGF levels,improve the treatment effect,and help improve the patient′s prognosis and quality of life.
Objective To explore the effect of Butylphthalide in the treatment of neurodegenerative diseases and hereditary diseases.Methods From December 2018 to December 2020,a total of 82 patients with neurodegenerative diseases and hereditary diseases who were admitted to the Department of Neurology,the Affiliated Dongnan Hospital of Xiamen University were selected as the study subjects.According to the order of admission (odd and even number),they were divided into the reference group and the study group,with 41 cases in each group.The reference group was given conventional medication for treatment,and the study group was given Butylphthalide on the basis of the reference group.The therapeutic effects,as well as the changes in neurological impairment,mental states,and living ability before and after treatment were compared between the two groups.Results The scores of neurological impairment and mental states in both groups of patients after treatment were lower than those before treatment,and the living ability score was higher than that before treatment,and the scores of neurological impairment and mental states in the study group were lower than those in the reference group,the living ability score was higher than that in the reference group,the differences were statistically significant(P<0.05).The total effective rate of treatment in the study group was higher than that in the reference group,and the difference was statistically significant(P<0.05).Conclusion Butylphthalide is very effective in the treatment of neurodegenerative diseases and hereditary diseases,and it can significantly reduce the degree of neurological impairment in patients.Also,it can greatly improve the life ability and mental state of patients,which is helpful for the preparation of data for later treatment,and this method can be popularized in clinical practice.